Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2816-2825

  Beck, R ^a   Dejeans, N ^a   Glorieux, C ^a   Pedrosa, R C ^b   Vosquez D ^c,e   Valderrama, J A ^c   Calderon, P B ^a,d   Verrax, J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD ARTURO PRAT   (Chile)

^e UNIVERSITY OF CHILE   (Chile)

Author keywords

Ascorbate; Cancer therapy; Fenton reaction; Hsp90; Oxidative stress; Protein cleavage; Redox cycling

Indexed keywords

ADAPHOSTIN; ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; ANTHRAQUINONE; APATONE; ARSENIC TRIOXIDE; ASCORBIC ACID; BENZYL ISOTHIOCYANATE; BORTEZOMIB; BUTHIONINE SULFOXIMINE; COUMARIN DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; IMEXON; KF 29163; LAWSONE; MENADIONE; MITOGEN ACTIVATED PROTEIN KINASE; NOVOBIOCIN; OCX 191; ONCOPROTEIN; PHENETHYL ISOTHIOCYANATE; QUINONE DERIVATIVE; RADICICOL; SALAZOSULFAPYRIDINE; STAT5 PROTEIN; SULFORAPHANE; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CELL DESTRUCTION; CANCER THERAPY; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; NONHUMAN; OXIDATIVE STRESS; PAPILLARY CARCINOMA; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN STABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 79959347917     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011256     Document Type: Article

References (97)

1. Xiao, X.; Zuo, X.; Davis, A. A.; McMillan, D. R.; Curry, B. B.; Richardson, J. A.; Benjamin, I. J. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J, 1999, 18, 5943-5952. (Pubitemid 29515671)
2. Powers, M. V.; Workman, P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett, 2007, 581, 3758-3769. (Pubitemid 47081010)
3. Mahalingam, D.; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting HSP90 for cancer therapy. Br J Cancer, 2009, 100, 1523-1529.
4. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, F. U. Pathways of chaperonemediated protein folding in the cytosol. Nat Rev Mol Cell Biol, 2004, 5, 781-791. (Pubitemid 39336272)
5. Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther, 2004, 3, 1021-1030. (Pubitemid 39199597)
6. Jakob, U.; Gaestel, M.; Engel, K.; Buchner, J. Small heat shock proteins are molecular chaperones. J Biol Chem, 1993, 268, 1517-1520. (Pubitemid 23033534)
7. Nathan, D. F.; Vos, M. H.; Lindquist, S. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proc Natl Acad Sci U S A, 1997, 94, 12949-12956. (Pubitemid 27518457)
8. Pratt, W. B. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med, 1998, 217, 420-434.
9. Lai, B. T.; Chin, N. W.; Stanek, A. E.; Keh, W.; Lanks, K. W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol, 1984, 4, 2802-2810. (Pubitemid 15113620)
10. Wandinger, S. K.; Richter, K.; Buchner, J. The Hsp90 chaperone machinery. J Biol Chem, 2008, 283, 18473-18477.
11. Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett, 2004, 562, 11-15. (Pubitemid 38388440)
12. Dutta, R.; Inouye, M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci, 2000, 25, 24-28. (Pubitemid 30060426)
13. Bergerat, A.; De Massy, B.; Gadelle, D.; Varoutas, P. C.; Nicolas, A.; Forterre, P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature, 1997, 386, 414-417. (Pubitemid 27154484)
14. Richter, K.; Soroka, J.; Skalniak, L.; Leskovar, A.; Hessling, M.; Reinstein, J.; Buchner, J. Conserved conformational changes in the ATPase cycle of human Hsp90. J Biol Chem, 2008, 283, 17757-17765.
15. Ali, M. M.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotidep23/ Sba1 closed chaperone complex. Nature, 2006, 440, 1013-1017.
16. McLaughlin, S. H.; Smith, H. W.; Jackson, S. E. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol, 2002, 315, 787-798. (Pubitemid 34729326)
17. McLaughlin, S. H.; Ventouras, L. A.; Lobbezoo, B.; Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J Mol Biol, 2004, 344, 813-826. (Pubitemid 39469222)
18. Taipale, M.; Jarosz, D. F.; Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol, 2010, 11, 515-528.
19. Kaur, J.; Ralhan, R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer, 1995, 63, 774-779.
20. Santarosa, M.; Favaro, D.; Quaia, M.; Galligioni, E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer, 1997, 33, 873-877. (Pubitemid 27287038)
21. Ralhan, R.; Kaur, J. Differential expression of Mr 70, 000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res, 1995, 1, 1217-1222.
22. Chant, I. D.; Rose, P. E.; Morris, A. G. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol, 1995, 90, 163-168.
23. Yufu, Y.; Nishimura, J.; Nawata, H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res, 1992, 16, 597-605.
24. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 2002, 8, S55-61. (Pubitemid 34297080)
25. Hanahan, D.; Weinberg, R. The hallmarks of cancer. Cell, 2000, 100, 57-70. (Pubitemid 30046295)
26. Neckers, L. Heat shock protein 90: the cancer chaperone. J Biosci, 2007, 32, 517-530. (Pubitemid 46708702)
27. Miller, P.; DiOrio, C.; Moyer, M.; Schnur, R. C.; Bruskin, A.; Cullen, W.; Moyer, J. D. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res, 1994, 54, 2724-2730. (Pubitemid 24173765)
28. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116, 855-867. (Pubitemid 38410730)
29. Murata, S.; Minami, Y.; Minami, M.; Chiba, T.; Tanaka, K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep, 2001, 2, 1133-1138. (Pubitemid 34055961)
30. Ballinger, C. A.; Connell, P.; Wu, Y.; Hu, Z.; Thompson, L. J.; Yin, L. Y.; Patterson, C. Identification of CHIP, a novel tetratricopeptide repeatcontaining protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol, 1999, 19, 4535-4545. (Pubitemid 29242026)
31. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets, 2003, 3, 349-358. (Pubitemid 37128321)
32. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425, 407-410. (Pubitemid 37187270)
33. Radanyi, C.; Le Bras, G.; Messaoudi, S.; Bouclier, C.; Peyrat, J. F.; Brion, J. D.; Marsaud, V.; Renoir, J. M.; Alami, M. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg Med Chem Lett, 2008, 18, 2495-2498.
34. Holmes, J. L.; Sharp, S. Y.; Hobbs, S.; Workman, P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res, 2008, 68, 1188-1197.
35. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C. G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther, 2008, 7, 162-170.
36. Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M. G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D. I.; Colombo, G.; Altieri, D. C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468. (Pubitemid 40719129)
37. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J. E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood, 2008, 112, 1886-1893.
38. Beck, R.; Verrax, J.; Gonze, T.; Zappone, M.; Pedrosa, R. C.; Taper, H.; Feron, O.; Calderon, P. B. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol, 2009, 77, 375-383.
39. Breinig, M.; Caldas-Lopes, E.; Goeppert, B.; Malz, M.; Rieker, R.; Bergmann, F.; Schirmacher, P.; Mayer, M.; Chiosis, G.; Kern, M. A. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology, 2009, 50, 102-112.
40. Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown, S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res, 2008, 14, 8302-8307.
41. Heath, E. I.; Hillman, D. W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H. C.; Tan, W.; Ivy, S. P.; Pili, R.; Carducci, M. A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res, 2008, 14, 7940-7946.
42. Ronnen, E. A.; Kondagunta, G. V.; Ishill, N.; Sweeney, S. M.; Deluca, J. K.; Schwartz, L.; Bacik, J.; Motzer, R. J. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs, 2006, 24, 543-546. (Pubitemid 44273031)
43. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol, 2008, 8, 370-374.
44. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem, 1999, 42, 260-266. (Pubitemid 29069861)
45. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res, 1999, 59, 2931-2938. (Pubitemid 29283134)
46. Arya, R.; Mallik, M.; Lakhotia, S. C. Heat shock genes - integrating cell survival and death. J Biosci, 2007, 32, 595-610. (Pubitemid 46708710)
47. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer, 2010, 10, 537-549.
48. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst, 2000, 92, 242-248. (Pubitemid 30099783)
49. Peterson, L. B.; Blagg, B. S. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorg Med Chem Lett, 2010, 20, 3957-3960.
50. Oberley, T.; Oberley, L. Antioxidant enzyme levels in cancer. Histol Histopathol, 1997, 12, 525-535. (Pubitemid 27240324)
51. Jaruga, P.; Zastawny, T. H.; Skokowski, J.; Dizdaroglu, M.; Olinski, R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett, 1994, 341, 59-64. (Pubitemid 24089190)
52. Kekec, Y.; Paydas, S.; Tuli, A.; Zorludemir, S.; Sakman, G.; Seydaoglu, G. Antioxidant enzyme levels in cases with gastrointesinal cancer. Eur J Intern Med, 2009, 20, 403-406.
53. Sun, Y.; Oberley, L.; Elwell, J.; Sierra-Rivera, E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int J Cancer, 1989, 44, 1028-1033. (Pubitemid 20017838)
54. Verrax, J.; Pedrosa, R.; Beck, R.; Dejeans, N.; Taper, H.; Calderon, P. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem, 2009, 16, 1821-1830.
55. Beck, R.; Pedrosa, R. C.; Dejeans, N.; Glorieux, C.; Leveque, P.; Gallez, B.; Taper, H.; Eeckhoudt, S.; Knoops, L.; Calderon, P. B.; Verrax, J. Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs, 2010.
56. Boonstra, J.; Post, J. A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene, 2004, 337, 1-13. (Pubitemid 38970100)
57. Toyokuni, S.; Okamoto, K.; Yodoi, J.; Hiai, H. Persistent oxidative stress in cancer. FEBS Lett, 1995, 358, 1-3.
58. Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat, 2004, 7, 97-110. (Pubitemid 38736063)
59. Sablina, A. A.; Budanov, A. V.; Ilyinskaya, G. V.; Agapova, L. S.; Kravchenko, J. E.; Chumakov, P. M. The antioxidant function of the p53 tumor suppressor. Nat Med, 2005, 11, 1306-1313. (Pubitemid 41752911)
60. Pelicano, H.; Feng, L.; Zhou, Y.; Carew, J. S.; Hileman, E. O.; Plunkett, W.; Keating, M. J.; Huang, P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. Journal of Biological Chemistry, 2003, 278, 37832-37839. (Pubitemid 37175311)
61. Lu, J.; Chew, E. H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A, 2007, 104, 12288-12293. (Pubitemid 47206130)
62. Thelander, L.; Graslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J Biol Chem, 1983, 258, 4063-4066. (Pubitemid 13080623)
63. Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; Sartorelli, A. C. Triapine (3-aminopyridine-2- carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol, 2000, 59, 983-991. (Pubitemid 30110814)
64. Svingen, P. A.; Tefferi, A.; Kottke, T. J.; Kaur, G.; Narayanan, V. L.; Sausville, E. A.; Kaufmann, S. H. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res, 2000, 6, 237-249. (Pubitemid 30064999)
65. Le, S. B.; Hailer, M. K.; Buhrow, S.; Wang, Q.; Flatten, K.; Pediaditakis, P.; Bible, K. C.; Lewis, L. D.; Sausville, E. A.; Pang, Y. P.; Ames, M. M.; Lemasters, J. J.; Holmuhamedov, E. L.; Kaufmann, S. H. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. Journal of Biological Chemistry, 2007, 282, 8860-8872. (Pubitemid 47093495)
66. Chandra, J.; Tracy, J.; Loegering, D.; Flatten, K.; Verstovsek, S.; Beran, M.; Gorre, M.; Estrov, Z.; Donato, N.; Talpaz, M.; Sawyers, C.; Bhalla, K.; Karp, J.; Sausville, E.; Kaufmann, S. H. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and-independent imatinib resistance. Blood, 2006, 107, 2501-2506. (Pubitemid 43345574)
67. Long, J.; Manchandia, T.; Ban, K.; Gao, S.; Miller, C.; Chandra, J. Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother Pharmacol, 2007, 59, 527-535. (Pubitemid 46122331)
68. Mukhopadhyay, I.; Sausville, E. A.; Doroshow, J. H.; Roy, K. K. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem, 2006, 281, 37330-37344. (Pubitemid 46042037)
69. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 2009, 8, 579-591.
70. Griffith, O. W.; Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). Journal of Biological Chemistry, 1979, 254, 7558-7560. (Pubitemid 10230219)
71. Lo, M.; Wang, Y. Z.; Gout, P. W. The x (c) - cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol, 2008, 215, 593-602. (Pubitemid 351632680)
72. Welsh, S. J.; Williams, R. R.; Birmingham, A.; Newman, D. J.; Kirkpatrick, D. L.; Powis, G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther, 2003, 2, 235-243.
73. Dikalov, S.; Landmesser, U.; Harrison, D. G. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. Implications for studies of Hsp90 and endothelial cell nitric-oxide synthase. J. Biol Chem, 2002, 277, 25480-25485. (Pubitemid 34951862)
74. Sreedhar, A. S.; Mihaly, K.; Pato, B.; Schnaider, T.; Stetak, A.; Kis-Petik, K.; Fidy, J.; Simonics, T.; Maraz, A.; Csermely, P. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide-and Hsp90-dependent events. J. Biol Chem, 2003, 278, 35231-35240. (Pubitemid 37102289)
75. Fukuyo, Y.; Inoue, M.; Nakajima, T.; Higashikubo, R.; Horikoshi, N. T.; Hunt, C.; Usheva, A.; Freeman, M. L.; Horikoshi, N. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Res, 2008, 68, 6324-6330.
76. Cysyk, R. L.; Parker, R. J.; Barchi, J. J., Jr.; Steeg, P. S.; Hartman, N. R.; Strong, J. M. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol, 2006, 19, 376-381.
77. McCollum, A. K.; Teneyck, C. J.; Sauer, B. M.; Toft, D. O.; Erlichman, C. Upregulation of heat shock protein 27 induces resistance to 17-allylaminodemethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res, 2006, 66, 10967-10975. (Pubitemid 44876996)
78. Nardai, G.; Sass, B.; Eber, J.; Orosz, G.; Csermely, P. Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch Biochem Biophys, 2000, 384, 59-67.
79. Clark, C. B.; Rane, M. J.; El Mehdi, D.; Miller, C. J.; Sachleben, L. R., Jr.; Gozal, E. Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radic Biol Med, 2009, 47, 1440-1449.
80. Taper, H.; de Gerlache, J.; Lans, M.; Roberfroid, M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer, 1987, 40, 575-579. (Pubitemid 17148749)
81. Taper, H.; Keyeux, A.; Roberfroid, M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res, 1996, 16, 499-503. (Pubitemid 26128515)
82. Noto, V.; Taper, H.; Jiang, Y.; Janssens, J.; Bonte, J.; De Loecker, W. Effects of sodium ascorbate (vitamin C) and 2-methyl-1, 4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer, 1989, 63, 901-906. (Pubitemid 19063198)
83. Verrax, J.; Cadrobbi, J.; Marques, C.; Taper, H.; Habraken, Y.; Piette, J.; Calderon, P. B. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 2004, 9, 223-233. (Pubitemid 38987599)
84. Verrax, J.; Delvaux, M.; Beghein, N.; Taper, H.; Gallez, B.; Buc Calderon, P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res, 2005, 39, 649-657. (Pubitemid 40846837)
85. Verrax, J.; Stockis, J.; Tison, A.; Taper, H. S.; Calderon, P. B. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol, 2006, 72, 671-680. (Pubitemid 44233542)
86. Verrax, J.; Vanbever, S.; Stockis, J.; Taper, H.; Calderon, P. B. Role of glycolysis inhibition and poly (ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer, 2007, 120, 1192-1197.
87. Dejeans, N.; Tajeddine, N.; Beck, R.; Verrax, J.; Taper, H.; Gailly, P.; Calderon, P. B. Endoplasmic reticulum calcium release potentiates the ER stress and cell death caused by an oxidative stress in MCF-7 cells. Biochem Pharmacol, 2010, 79, 1221-1230.
88. Tareen, B.; Summers, J.; Jamison, J.; Neal, D.; McGuire, K.; Gerson, L.; Diokno, A. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int J Med Sci, 2008, 5, 62-67. (Pubitemid 351871013)
89. Obermann, W. M.; Sondermann, H.; Russo, A. A.; Pavletich, N. P.; Hartl, F. U. In vivo function of Hsp90 is dependent on AT P binding and AT P hydrolysis. J Cell Biol, 1998, 143, 901-910. (Pubitemid 28547391)
90. Stadtman, E. R. Protein oxidation and aging. Free Radic Res, 2006, 40, 1250-1258. (Pubitemid 44698274)
91. Verrax, J.; Cadrobbi, J.; Delvaux, M.; Jamison, J. M.; Gilloteaux, J.; Summers, J. L.; Taper, H. S.; Buc Calderon, P. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem, 2003, 38, 451-457. (Pubitemid 36588911)
92. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293, 876-880. (Pubitemid 32743979)
93. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002, 2, 117-125. (Pubitemid 41039112)
94. Winterbourn, C. C.; Stern, A. Human red cells scavenge extracellular hydrogen peroxide and inhibit formation of hypochlorous acid and hydroxyl radical. J Clin Invest, 1987, 80, 1486-1491. (Pubitemid 18027795)
95. Chen, Q.; Espey, M.; Krishna, M.; Mitchell, J.; Corpe, C.; Buettner, G.; Shacter, E.; Levine, M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A, 2005, 102, 13604-13609. (Pubitemid 41420895)
96. Song, Y.; Buettner, G. R. Thermodynamic and kinetic considerations for the reaction of semiquinone radicals to form superoxide and hydrogen peroxide. Free Radic Biol Med, 2010, 49, 919-962.
97. Vasquez, D.; Verrax, J.; Valderrama, J. A.; Buc Calderon P. Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death. Invest New Drugs, 2011 (In press).